Sarepta Therapeutics (NASDAQ:SRPT) Announces Earnings Results

Sarepta Therapeutics (NASDAQ:SRPT) released its earnings results on Wednesday. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84, RTT News reports. The firm had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.44) EPS.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded up $4.24 during trading hours on Wednesday, hitting $130.90. 854,891 shares of the stock were exchanged, compared to its average volume of 997,063. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The stock has a market capitalization of $12.37 billion, a P/E ratio of -20.88 and a beta of 0.94. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89. The business’s 50-day moving average is $125.80 and its two-hundred day moving average is $110.42.

Analyst Ratings Changes

A number of research analysts have recently commented on SRPT shares. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. UBS Group upped their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Citigroup upped their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, Wedbush reissued an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $156.60.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.